Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature

Journal of Vascular Surgery

Volumn 55, Issue 2, 2012, Pages 400-405

  Lammer, Johannes ^a   Scheinert, Dierk ^b   Vermassen, Frank ^c   Koppensteiner, Renate ^a   Hausegger, Klaus A ^d   Schro, Herman ^e   Menon, Rajeev M ^f   Schwartz, Lewis B ^f  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d GENERAL HOSPITAL KLAGENFURT   (Austria)

^e Ziekenhuis Oost Limburt   (Belgium)

^f ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS;

AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG ELUTING STENT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMPLANTATION; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; VASCULARIZATION;

AGED; CARDIOVASCULAR AGENTS; CONSTRICTION, PATHOLOGIC; DRUG-ELUTING STENTS; ENDOVASCULAR PROCEDURES; EUROPE; FEMALE; FEMORAL ARTERY; HUMANS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RECURRENCE; SIROLIMUS; TREATMENT OUTCOME;

EID: 84856102126     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2011.08.048     Document Type: Article

References (46)

1. P.W. Serruys, M.J. Kutryk, A.T. Ong Coronary-artery stents N Engl J Med 354 2006 483 495 (Pubitemid 43200299)
2. G.W. Stone, J.W. Moses, S.G. Ellis, J. Schofer, K.D. Dawkins, M.C. Morice et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 2007 998 1008 (Pubitemid 46376800)
3. O.C. Marroquin, F. Selzer, S.R. Mulukutla, D.O. Williams, H.A. Vlachos, R.L. Wilensky et al. A comparison of bare-metal and drug-eluting stents for off-label indications N Engl J Med 358 2008 342 352 (Pubitemid 351159233)
4. G.W. Vetrovec, D. Rizik, C. Williard, D. Snead, V. Piotrovski, G. Kopia Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions Catheter Cardiovasc Interv 67 2006 32 37 (Pubitemid 43062605)
5. M. Wiemer, A. Seth, P. Chandra, J. Neuzner, G. Richardt, J.J. Piek et al. Systemic exposure of everolimus after stent implantation: a pharmacokinetic study Am Heart J 156 2008 751e.1-7
6. J. Lammer, M. Bosiers, T. Zeller, M. Schillinger, E. Boone, M.J. Zaugg et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease J Vasc Surg 54 2011 394 401
7. M. Schillinger, S. Sabeti, C. Loewe, P. Dick, J. Amighi, W. Mlekusch et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery N Engl J Med 354 2006 1879 1888 (Pubitemid 43872689)
8. O. Schlager, P. Dick, S. Sabeti, J. Amighi, W. Mlekusch, E. Minar et al. Long-segment SFA stentingthe dark sides: in-stent restenosis, clinical deterioration, and stent fractures J Endovasc Ther 12 2005 676 684 (Pubitemid 43100925)
9. M. Schillinger, S. Sabeti, P. Dick, J. Amighi, W. Mlekusch, O. Schlager et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting Circulation 115 2007 2745 2749 (Pubitemid 46842791)
10. S. Sabeti, A. Czerwenka-Wenkstetten, P. Dick, O. Schlager, J. Amighi, I. Mlekusch et al. Quality of life after balloon angioplasty versus stent implantation in the superficial femoral artery: findings from a randomized controlled trial J Endovasc Ther 14 2007 431 437 (Pubitemid 350154987)
11. T. Zeller, N. Saratzis, D. Scheinert, E. Minar, J.P. Beregi, M. Schillinger et al. Non-randomized, prospective, multi-centre evaluation of the ABSOLUTE 0.35 peripheral self-expanding stent system for occluded or stenotic superficial femoral or proximal popliteal arteries (ASSESS Trial): acute and 30-day results J Cardiovasc Surg 48 2007 719 726 (Pubitemid 350268016)
12. C. Dunn, K.F. Croom Everolimus: a review of its use in renal and cardiac transplantation Drugs 66 2006 547 570
13. H.J. Eisen, E.M. Tuzcu, R. Dorent, J. Kobashigawa, D. Mancini, H.A. Valantine-von Kaeppler et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients N Engl J Med 349 2003 847 858 (Pubitemid 37025404)
14. M.I. Lorber, S. Mulgaonkar, K.M. Butt, E. Elkhammas, R. Mendez, P.R. Rajagopalan et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study Transplantation 80 2005 244 252 (Pubitemid 41061682)
15. R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, S. Bracarda et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
16. P.J. Houghton Everolimus Clin Cancer Res 16 2010 1368 1372
17. B. Kahan, R. Wong, C. Carter, S. Katz, J. Von Fellenberg, C. Van Buren et al. A phase 1 study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-prednisone-treated renal transplants recipients Transplantation 68 1999 1100 1106 (Pubitemid 29517697)
18. G.I. Kirchner, I. Meier-Wiedenbach, M.P. Manns Clinical pharmacokinetics of everolimus Clin Pharmacol Ther 43 2004 83 95 (Pubitemid 38283132)
19. K. Budde, H.H. Neumayer, G. Lehne, M. Winkler, I.A. Hauser, A. Lison et al. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients Nephrol Dial Transplant 19 2004 2606 2614 (Pubitemid 39360111)
20. J.M. Kovarik, B.D. Kahan, B. Kaplan, M. Lorber, M. Winkler, M. Rouilly et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine Clin Pharmacol Ther 69 2001 48 56 (Pubitemid 32108671)
21. J.M. Kovarik, D. Beyer, M.N. Bizot, Q. Jiang, M. Shenouda, R.L. Schmouder Blood concentrations of everolimus are markedly increased by ketoconazole J Clin Pharmacol 45 2005 514 518 (Pubitemid 40562941)
22. A. Farb, M. John, E. Acampado, F.D. Kolodgie, M.F. Prescott, R. Virmani Oral everolimus inhibits in-stent neointimal growth Circulation 106 2002 2379 2384 (Pubitemid 35244741)
23. R. Waksman, R. Pakala, R. Baffour, D. Hellinga, R. Seabron, F. Kolodgie et al. Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries Cardiovasc Revasc Med 7 2006 179 184 (Pubitemid 44292070)
24. G.W. Stone, M. Midei, W. Newman, M. Sanz, J.B. Hermiller, J. Williams et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 2008 1903 1913 (Pubitemid 351574920)
25. N. Kukreja, Y. Onuma, P.W. Serruys Xience V everolimus-eluting coronary stent Expert Rev Med Dev 6 2009 219 229
26. S. Nakaji, T. Yamamoto Membranes for therapeutic apheresis Ther Apher 6 2002 267 270
27. T. Cicchetti, R.P. Senatore, F. Frandina, S. Ferrari, U. Striano, M. Milei et al. Dialysis treatment using an ethylene vinyl alcohol membrane and no anticoagulation for chronic uremic patients Artif Organs 17 1993 816 819 (Pubitemid 23288695)
28. Y. Ishii, S. Yano, H. Kanai, A. Maezawa, A. Tsuchida, R. Wakamatsu et al. Evaluation of blood coagulation-fibrinolysis system in patients receiving chronic hemodialysis Nephron 73 1996 407 412 (Pubitemid 26229693)
29. A.J. Molyneux, S. Cekirge, I. Saatci, G. Gl Cerebral aneurysm multicenter European Onyx (CAMEO) Trial: results of a prospective observational study in 20 European centers AJNR Am J Neuroradiol 25 2004 39 51 (Pubitemid 38129477)
30. M.J. Bratby, E.D. Lehmann, J. Bottomley, D.O. Kessel, A.A. Nicholson, S.J. Mc Pherson et al. Endovascular embolization of visceral artery aneurysms with ethylene-vinyl alcohol (Onyx): a case series Cardiovasc Interv Radiol 29 2006 1125 1128 (Pubitemid 44661973)
31. M. Ayad, E. Eskiglu, M.R.A. Onyx A unique neuroembolic agent Expert Rev Med Dev 3 2006 705 715
32. P. Gailloud Endovascular treatment of cerebral arteriovenous malformations Tech Vasc Interventional Radiol 8 2005 118 128 (Pubitemid 41821372)
33. J.W. Moses, M.B. Leon, J.J. Popma, P.J. Fitzgerald, D.R. Holmes, C. O'Shaughnessy et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323 (Pubitemid 37186209)
34. H. Zhao, A. Nikanorov, R. Virmani, L.B. Schwartz Long-term effects of everolimus-eluting self-expanding stent implantation in an experimental model of peripheral vascular intervention [Abstract] J Vasc Surg 53 2011 89S 90S
35. S.H. Duda, M. Bosiers, J. Lammer, D. Scheinert, T. Zeller, A. Tielbeek et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II Trial J Vasc Interv Radiol 16 2005 331 338 (Pubitemid 40354849)
36. J.R. Laird Limitations of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popliteal arteries J Endovasc Ther 13 Suppl II 2006 II-30 II-40
37. M. Schillinger, E. Minar Endovascular stent implantation for treatment of peripheral artery disease Eur J Clin Invest 37 2007 165 170
38. S.H. Duda, M. Bosiers, J. Lammer, D. Scheinert, T. Zeller, V. Oliva et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial J Endovasc Ther 13 2006 701 710 (Pubitemid 44907633)
39. S.H. Duda, B. Pusich, G. Richter, P. Landwehr, V.L. Oliva, A. Tielbeek et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results Circulation 106 2002 1505 1509
40. A.W. Heldman, A.O. Ragheb Paclitaxel persists in vessel wall after rapid delivery from nonpolymeric paclitaxel coating on self-expanding Nitinol stents Am J Cardiol 94 Suppl 6A 2004 27E
41. A.J. Lansky, R.A. Costa, G.S. Mintz, Y. Tsuchiya, M. Midei, D.A. Cox et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER Clinical Trial Circulation 109 2004 1948 1954 (Pubitemid 38544484)
42. H.H. Neumayer, K. Paradis, A. Korn, C. Jean, L. Fritsche, K. Budde et al. Entry-into-human study with the novel immunosuppressant SDZ RAD (everolimus) in stable renal transplant recipients Br J Pharmacol 48 1999 694 703 (Pubitemid 29520593)
43. S. Oudard, J. Medioni, J. Aylllon, E. Barrascourt, R.T. Elaidi, J. Balcaceres et al. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma Expert Rev Anticancer Ther 9 2009 705 717
44. T. Grgic, L. Mis, J.M. Hammond Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma Ann Pharmacother 45 2011 78 83
45. J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, E. Van Cutsem et al. Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
46. D.A. Krueger, M.M. Care, K. Holland, K. Agricola, C. Tudor, P. Mangeshkar et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis N Engl J Med 363 2010 1801 1811